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Abstract: Alzheimer’s disease (AD) is a burgeoning social and healthcare problem. Cholinesterase 
inhibitors (ChEIs) are employed for symptomatic treatment of AD, but often elicit adverse drug 
reactions (ADRs). Herein, the potency of the ChEIs, donepezil, tacrine, berberine, and galantamine 
to inhibit human or Torpedo californica acetylcholinesterase (tcAChE) proteins were evaluated. The 
efficacy of dual-drug combinations to inhibit human AChE directly and within differentiated neu-
rons was also quantified. ChEI potency was in the order: donepezil > tacrine > berberine > galanta-
mine for both AChEs. Dual-drug combinations of berberine and tacrine (BerTac), berberine and 
galantamine (BerGal), and tacrine and donepezil (TacDon) all produced synergistic outcomes for 
AChE inhibition. Donepezil and berberine (DonBer) and tacrine and galantamine (TacGal) elicited 
antagonistic responses. Donepezil and galantamine (DonGal) was synergistic for human AChE but 
antagonistic for tcAChE. After application of dual-drug combinations to neuronal cells, BerTac, 
BerGal, DonGal, and DonBer all showed synergistic inhibition of AChE, TacDon additive, and Tac-
Gal antagonistic effects. BerGal produced the most potent synergism and reduced total drug dose 
by 72%. Individual ChEIs or dual-drug combinations were relatively non-toxic to neuronal cells, 
and only reduced cell viability at concentrations two–three orders of magnitude greater than that 
required to inhibit AChE. In summary, dual-drug combinations of ChEIs potentially represent a 
novel means of AD patient treatment, with reduced and more cost-effective drug dosing, and low-
ered likelihood of ADRs. 
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1. Introduction 
Approximately 50 million people globally suffer from dementia and the number is 
expected to triple by 2050 [1]. Alzheimer’s disease (AD) represents the majority of demen-
tia cases [2,3]. AD patients suffer from broad symptomology that includes confusion, pe-
riods of memory loss and cognitive decline, and with disease progression, AD patients 
lose the ability to perform daily activities and tasks with an associated loss of independ-
ence [4]. The reduced cognition aligns with a loss of neuronal transmission and function-
ality, as well as a loss of neuronal mass [5,6]. AD patients experience brain cortical atrophy 
primarily within the frontotemporal lobes, notably within the hippocampal and entorhi-
nal cortex [5,6], consistent with the loss of cognitive function and memory attributed to 
these brain regions [7]. 
A reduction of signaling from the neurotransmitter acetylcholine (ACh) led to the 
concept of a “cholinergic hypothesis” to explain some of the cognitive deficits experienced 
by AD patients [8,9]. This cholinergic signaling decline provides the basis for the current 
first-line drug treatment for mild-to-moderate AD: employment of cholinesterase inhibi-
tors (ChEIs) such as donepezil, rivastigmine, and galantamine [10–12]. ChEIs transiently 
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inhibit the activity of acetylcholinesterase (AChE), which is predominantly localized to 
the pre-synaptic membrane in the CNS and the synaptic basal lamina of the neuromuscu-
lar junction [13,14]. This (reversible) inhibition of AChE within the central nervous system 
(CNS) is therefore an attempt to prolong ACh signaling. 
ChEIs are either of synthetic (e.g., donepezil and tacrine) or of plant origin (e.g., 
galantamine, huperzine A, and berberine). The current US Food and Drug Administration 
(FDA) approved ChEIs (donepezil, galantamine, and rivastigmine) have proved benefi-
cial for patients with mild-to-moderate AD [15,16]; however, they are limited by induction 
of undesired side effects, and ultimately, only provide symptomatic rather than curative 
benefit. Nevertheless, the search continues for useful next-generation ChEIs with similar 
efficacy to the current drugs but with fewer adverse drug reactions (ADRs). Furthermore, 
additional beneficial properties such as provision of antioxidants, has garnered the use of 
certain plant extracts and phytochemicals as potential next-generation ChEIs [17–22]. 
To achieve efficacy, treatment with ChEIs often requires titration, typically with an 
increased drug dose after four weeks [15]. At the starting or increased drug dose there is 
still a risk of idiosyncratic ADRs. Furthermore, for chronically dosed patients, therapeutic 
effects may be limited (at a fixed dosing regimen) due to neurobiological adaptation and 
drug tolerance, promoting the need for further increased dosing. Therefore, the lowest 
drug dose possible that still achieves therapeutic efficacy will reduce the likelihood of in-
duction of toxicity. 
One approach to provide suitable drug efficacy to treat AD, but at a lower dosing 
regimen, is via combination drug therapy [23]. Combination drug therapy can provide a 
fixed-dose of two or more active pharmaceutical agents within a single dosing entity. In 
this study, the efficacy of individual ChEIs as well as two-drug combinations were as-
sessed via their ability to directly inhibit AChE. The FDA-approved synthetic ChEIs, 
donepezil and tacrine, were investigated, as well as two plant alkaloids (phytochemicals), 
galantamine (also FDA approved) and berberine. Berberine was included as it is a phyto-
chemical with documented AChE affinity and binding, antioxidant properties, and pro-
posed as a potential anti-AD drug [24–26]. 
2. Materials and Methods 
2.1. Chemicals and Reagents 
Recombinant human acetylcholinesterase (hAChE), Torpedo californica acetylcholin-
esterase (tcAChE), acetylthiocholine iodide (ATCI), 5,5’-dithiobis-(2-nitrobenzoic acid) 
(DTNB), all-trans-retinoic acid, thiazolyl blue tetrazolium bromide (MTT), isopropanol, 
dimethyl sulfoxide (DMSO), and the drugs donepezil hydrochloride, MW = 415.95 g/mol; 
tacrine hydrochloride, MW = 234.72; berberine hydrochloride, MW = 371.82 g/mol; and 
galantamine hydrobromide, MW = 368.27 g/mol, were all purchased from Sigma-Aldrich 
(Poole, UK). Dulbecco’s Modified Eagle’s Medium (DMEM), fetal bovine serum (FBS), al-
bumin, and poly-D-lysine (PDL) were purchased from Thermofisher Scientific (Rochester, 
UK). Unless specified differently, all other chemicals were from Sigma-Aldrich (Poole, 
UK). 
2.2. Enzymatic Activity Assays 
A microtiter plate version of the Ellman’s assay was used to determine the activity of 
human and Torpedo californica acetylcholinesterase enzymes [27]. Assays were undertaken 
in the presence of either individual drugs or two-drug combinations. Each assay data 
point within a 96-well plate contained 40 µL of 0.01 M DTNB, 46 µL of 0.1 M (pH 8.0) 
phosphate buffer, 2 µL of 0.075 M ATCI substrate, and 10 µL of drug or dual-drug com-
bination. Drug concentrations were prepared according to Supplementary Table S1 [28]. 
Enzymatic cleavage of the ATCI substrate was initiated by addition of 2 µL of 0.5 U/mL 
AChE enzyme. The reaction was undertaken for 30 min at room temperature, protected 
from the light, before the color change was read at 412 nm using a Multiskan Spectrum 
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plate reader (Thermo Electron Corporation, Vantaa, Finland). Under these assay condi-
tions, a final color change was reached (results not included) such that an end-point assay 
measurement was taken [29]. 
Initially, assays were undertaken with a broad drug concentration range (0.1, 1, 10, 
100 and 1000 µM) to determine an approximate concentration producing 50% inhibition 
of AChE (IC50) (results not included). These scoping experiments enabled us to quantify 
an approximate IC50 for subsequent dose-response experiments. Two-fold serial dilutions 
at the approximate drug IC50 concentrations were prepared i.e., 0.25x, 0.5x, 1x, 2x, and 4x 
the IC50 concentrations. These concentrations were also used for dual-drug combination 
experiments. Experiments undertaken in the absence of inhibitor were designated as 100% 
enzymatic activity. Assays were performed in duplicates from which a mean was calcu-
lated. 
AChE Assay Using Neuroblastoma Cells 
Neuroblastoma SH-SY5Y cells (passage #15) were grown in DMEM containing 10% 
FBS in 6-well plates that had been pre-coated with 50 µg/mL PDL. Cells were grown to 
≈50% confluency at 37 °C within an atmosphere of 5% CO2 and 95% humidity. Growth 
media was replaced and cells differentiated in DMEM/F12 media (without choline or phe-
nol red) containing 1% FBS and 10 µM all-trans-retinoic acid. Growth media was changed 
every other day and differentiation of neurons was monitored by light microscopy. After 
6 days, neurons were fully differentiated, and then treated with drugs across the broad 
concentration range of 0.1, 1, 10, 100, and 1000 µM; either as individual drugs or in two-
drug combinations. The cell-based Ellman’s assay described by Li et al. (2017) [29] was 
modified for 6-well plates. A final reaction volume of 400 µL was used, comprised of 190 
µL of 0.01 M DTNB, 200 µL of 0.1 M (pH 8.0) phosphate buffer and 10 µL of 0.075 M ATCI 
substrate. AChE present on the cell membranes of the differentiated neuronal cells pro-
vided the enzymatic activity to drive the hydrolysis of ATCI. Plates were placed in the 37 
°C cell culture incubator for 30 min. The reaction mixture was then removed from the 
plate wells and transferred into 1.5 mL Eppendorf tubes. These were centrifuged at 12,000 
x g for 5 min to settle cellular debris. The supernatant was removed and optical density 
measured at a wavelength of 412 nm using a Multiskan Spectrum plate reader (Thermo 
Electron Corporation, Vantaa, Finland). 
2.3. Computational Analysis 
Percentage inhibition of AChE from in vitro assays in response to application of in-
dividual or dual-drug ChEIs were calculated using CompuSyn software 
(http://www.combosyn.com/index.html). The CompuSyn report provided IC50 and com-
bination index (CI) values for individual drug or two-drug combinations and was used to 
plot dose-response effect curves and CI plots, respectively [30]. 
2.4. Cytotoxicity Assays 
A MTT assay was used to assess the cytotoxicity of either the individual drugs or 
dual-drug combinations using the SH-SY5Y neuroblastoma cell line. SH-SY5Y cells were 
seeded in 96-well plates (passage #15) at a cell density of 3 × 104 cells/well in DMEM con-
taining 10% FBS. Cells were grown until 80–85% confluent and then treated with drugs 
over a concentration range of 0.01, 1, 10, 100, and 1000 µg/mL in cell culture media. After 
an incubation of 48 h within the 37 °C incubator, cell culture media was removed and 
replaced with fresh growth media containing 0.5% (w/v) MTT. Plates were incubated for 
4 h at 37 °C, before removal of the media and replacement with 1:1 (v/v) isopropa-
nol:DMSO. Formation of formazan was quantified by color generation at a wavelength of 
570 nm using a Multiskan Spectrum plate reader (Thermo Electron Corporation, Vantaa, 
Finland). Cell viability of cells treated with drugs was quantified by comparison to un-
treated control cells, set at 100% viability. 
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2.5. Statistical Analysis 
Values generated for IC50 and for the dual-drug CI were determined using Com-
puSyn software. Cell viability data was calculated by non-linear regression (inhibitor vs. 
normalized response—variable slope) using a model of best-fit values of four data points 
using GraphPad Prism V.7 (https://www.graphpad.com/scientific-software/prism/). For 
cell viability assays, a one-way ANOVA was performed to determine significant changes 
after treatments compared to control cell viability, set at 100%. 
3. Results 
3.1. Drug Inhibition of AChE Protein In Vitro 
The drugs donepezil, tacrine, berberine, and galantamine (Figure 1) were incubated 
with recombinant human acetylcholinesterase (hAChE) and Torpedo californica acetylcho-
linesterase (tcAChE), and the level of enzymatic inhibition quantified. Dose-response ef-
fect curves were generated and a plot of fractional affect (Fa) 0.5 (representing the concen-
tration producing 50% enzyme inhibition (IC50) against dose plotted (Figure 2A,B). The 
inhibition curves showed that the potency of the drugs to inhibit AChE was in the order: 
donepezil > tacrine > berberine > galantamine for both the human (h) and Torpedo califor-
nica (tc) enzymes. Berberine and galantamine inhibited both species of AChE with similar 
potency. Donepezil was more potent an inhibitor of human AChE, and tacrine was ≈2.7-
fold more potent for the T. californica enzyme, as detailed in Table 1. 
 
Figure 1. Structures of the cholinesterase inhibitor (ChEI) drugs. 
  







Figure 2. Drug inhibition of acetylcholinesterase (AChE) protein in vitro: Human AChE (A) or 
Torpedo californica AChE (B) were incubated with donepezil (Don), tacrine (Tac), berberine (Ber), 
and galantamine (Gal) and the level of cholinesterase inhibition quantified. Dose-response effect 
curves were generated as fractional affect (Fa) 0.5 (representing the concentration producing 50% 
enzyme inhibition (IC50) against dose. Combination index (CI) plots for dual-drug inhibition of 
human AChE (C) and Torpedo californica AChE (D). BerTac = berberine and tacrine; BerGal = ber-
berine and galantamine; TacDon = tacrine and donepezil; DonGal = donepezil and galantamine; 
DonBer = donepezil and berberine; TacGal = tacrine and galantamine. 
Table 1. Quantitation of interactions between ChEI drugs, dual-drug combinations, and human 
and Torpedo californica AChE. 
Drug or Drug Combi-
nation 
CI Value 
Acetycholinesterase Inhibition (IC50) (nM) 
Donepezil Tacrine Berberine Galantamine 
Don  
57 (h)    
91 (tc) 














302 (h) 1451 (h) 
 




1101 (h) 1101 (h) 
744 (tc) 1355 (tc) 1355 (tc) 
TacDon 
887 (h) 27 (h) 299 (h) 
  
697 (tc) 29 (tc) 103 (tc) 
DonGal 
876 (h) 29 (h) 
  
1538 (h) 
1216 (tc) 51 (tc) 2729 (tc) 
DonBer 











1139 (tc) 156 (tc) 2344 (tc) 
Don = Donepezil; Tac = tacrine; Ber = berberine; Gal = galantamine. BerTac = berberine and tacrine; 
BerGal = berberine and galantamine; TacDon = tacrine and donepezil; DonGal = donepezil and 
galantamine; DonBer = donepezil and berberine; TacGal = tacrine and galantamine. (h) = human; tc 
= Torpedo californica. Combination Index values (CI): Synergism: CI < 1; Additive: CL = 1; Antago-
nism: CI > 1. 
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The ability of two-drug combinations to inhibit human and tcAChE were then con-
sidered. Mixtures of berberine and tacrine (BerTac), berberine and galantamine (BerGal), 
tacrine and donepezil (TacDon), donepezil and galantamine (DonGal), donepezil and ber-
berine (DonBer), and tacrine and galantamine (TacGal) were assayed at combinations of 
0.25x, 0.5x, 1x, 2x, and 4x, as detailed in Supplementary Table S1. A combination index 
(CI) plot (from CompuSyn) of the different drug combinations was generated for the frac-
tional affect (Fa) 0.5 (IC50 values) (Figure 2C,D). The central line with a CI of 1 reflects the 
point at which drug combinations had an additive effect. CI values below that line are 
indicative of synergism (CI < 1), and CI values above the line represent antagonism (CI > 
1) [31]. 
The drug combinations, BerTac, BerGal, and TacDon produced synergistic outcomes, 
whereas DonBer and TacGal were antagonistic. DonGal was synergistic for human AChE 
but antagonistic for tcAChE (Table 1). The most potent synergistic combination to inhibit 
human or tcAChE was from a berberine and galantamine mixture (BerGal). This was in 
stark contrast to their individual drug potencies that displayed higher IC50 values than 
either of the synthetic ChEIs, donepezil or tacrine. If BerGal was used at a 1:1 combination, 
IC50 values were lowered to 1.101 µM for hAChE inhibition and 1.355 µM for tcAChE 
(Table 2). 
Table 2. Quantitation of interactions between ChEI drugs, dual-drug combinations, and neuronal 
AChE. 
Drug or Drug 
Combination 
CI Value 
Acetylcholinesterase Inhibition (IC50) (nM) 
Donepezil Tacrine Berberine Galantamine 
Don  81    
Tac   1019   
Ber    4844  
Gal     7009 
BerTac 686  348 1670  
BerGal 575   1648 1648 
TacDon 963 41 461   
DonGal 804 40   2152 
DonBer 834 36  1907  
TacGal 1100  660  3169 
Don = donepezil; Tac = tacrine; Ber = berberine; Gal = galantamine. BerTac = berberine and tacrine; 
BerGal = berberine and galantamine; TacDon = tacrine and donepezil; DonGal = donepezil and 
galantamine; DonBer = donepezil and berberine; TacGal = tacrine and galantamine. (h) = human; tc 
= Torpedo californica. Combination index values (CI); Synergism: CI < 1; Additive: CI = 1; Antago-
nism: CI > 1. 
3.2. Drug Inhibition of AChE within Differentiated Neurons 
Human derived neuroblastoma SH-SY5Y cells were differentiated with retinoic acid 
to produce neurons of a cholinergic phenotype [32–35], and then challenged with individ-
ual ChEIs and two-drug combinations, prepared according to Supplementary Table S1. 
Dose effect curves for the tested drugs were generated (Figure 3A), and showed that the 
relative drug potency observed for protein assays (Figure 2A,B) was mirrored with human 
neuronal cells grown in culture, with potency in the order donepezil > tacrine > berberine 
> galantamine. However, the cell-based assay curves were flatter and generated IC50 val-
ues higher than those obtained with purified hAChE (Table 2). 




Figure 3. Drug inhibition of AChE within SH-SY5Y cells: Human neuroblastoma cells were incu-
bated with donepezil (Don), tacrine (Tac), berberine (Ber), and galantamine (Gal) and the level of 
cholinesterase inhibition quantified (A). Combination index (CI) plot of dual-drug inhibition of 
AChE (B). BerTac = berberine and tacrine; BerGal = berberine and galantamine; TacDon = tacrine 
and donepezil; DonGal = donepezil and galantamine; DonBer = donepezil and berberine; TacGal = 
tacrine and galantamine. 
A CI plot of the different drug combinations against the fractional affect (Fa) 0.5 (IC50 
values) revealed that for the first assayed point (0.25x), only TacDon, DonGal, and TacGal 
generated values close to the central line, in keeping with additive effects, whereas BerTac, 
BerGal, and DonBer effects were all synergistic. However, at higher drug concentrations, 
all of the tested combinations (BerTac, BerGal, TacDon, DonGal, DonBer, and TacGal) dis-
played synergistic effects (Figure 3B). 
The CI values generated for the drug combinations are listed in Table 2, and show 
that the drug combinations BerTac, BerGal, DonGal, and DonBer all show synergistic in-
hibition of AChE at their IC50 concentrations. The TacDon drug combination approached 
additive effects, while TacGal was antagonistic at IC50 concentrations. 
The BerGal drug combination had the most potent inhibitory effect (CI = 0.575). The 
individual IC50 values for berberine and galantamine were 4.844 µM and 7.009 µM, re-
spectively. Hence, a drug combination of 1.648 µM of each drug (IC50 values for a 1:1 drug 
ratio) would in theory have similar efficacy as either drug, but with a substantial reduction 
of dose: 34% of the original berberine and 24% of galantamine. Figure 4A is a pictorial 
representation of this virtual BerGal combination pill and has a net reduction of 72% of 
total drug dose. 
  
(A) (B) 
Figure 4. Virtual ChEI dual-drug combination pills: A virtual berberine and galantamine (BerGal) 
pill would have a 72% reduction of total drug dose (A). A virtual berberine and tacrine (BerTac) 
pill would have a 66% reduction of total drug dose (B). 
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Similarly, for the second most favorable drug combination of BerTac (CI = 0.686), 
there would be a beneficial reduction from their individual drug concentrations: IC50 val-
ues of 4.844 µM and 1.019 µM reduced to 1.670 µM and 0.348 µM, respectively. A theo-
retical BerTac pill would only require 28% and 6% of the individual doses of berberine 
and tacrine, respectively, with a net 66% reduction of total drug dose (Figure 4B). 
3.3. Cytotoxicity of Individual and Dual-Drug ChEI Combinations to Neuronal Cells 
SH-SY5Y cells were treated with the ChEIs and two-drug combinations, and cell vi-
ability assessed using a MTT assay. Drugs were applied over a concentration range of 0.1, 
1, 10, 100, and 1000 µg/mL for 48 h and cell viability compared with vehicle-treated control 
cells (set at 100% viability). The toxicity of the individual ChEIs to neuronal cells is shown 
in Figure 5. At the lowest concentration employed, 0.1 µM, none of the drugs were toxic 
to neurons (marked as non-significant changes from controls). A concentration of 1 µM 
(and above) of donepezil or berberine was able to induce toxicity, whereas at least 10 µM 
of tacrine or 100 µM of galantamine was needed to reduce cell viability. The drug (inhib-
itor) concentration that reduced cell viability by 50% (IC50) was determined by non-linear 
regression, with values listed in Table 3. The order of toxicity of the ChEIs was donepezil 
> tacrine > berberine > galantamine. Dual-drug combinations were generally more toxic 
to neuronal cells with lower IC50 values, apart from a BerGal combination that was rela-
tively non-toxic (Figure 5 and Table 3). 
 
Figure 5. Cytotoxicity of individual and dual-drug ChEI combinations to SH-SY5Y cells: Human 
neuroblastoma cells were incubated with donepezil (Don), tacrine (Tac), berberine (Ber), and 
galantamine (Gal) or dual-drug combinations: BerTac (berberine and tacrine), BerGal (berberine 
and galantamine), TacDon (tacrine and donepezil), DonGal (donepezil and galantamine), DonBer 
(donepezil and berberine), and TacGal (tacrine and galantamine), and cell viability quantified us-
ing a MTT assay. Significant changes were quantified using a one-way ANOVA. ns = non-signifi-
cant effect on cell viability. All other histograms not marked with ns, displayed significant changes 
from controls. 
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Table 3. Neurotoxicity of ChEI drugs and dual-drug combinations against SH-SY5Y neuroblas-
toma cells. 
Drug or Drug Combination Cell Cytotoxicity Log IC50 (µg/mL) 
Don 2.31 ± 0.057  
Tac 2.53 ± 0.091  
Ber 2.98 ± 0.010  
Gal 4.10 ± 0.041  
DonBer 2.01 ± 0.043  
BerTac 2.16 ± 0.031  
BerGal 3.01 ± 0.046  
TacDon 2.08 ± 0.038  
TacGal 2.16 ± 0.052 
DonGal 2.08 ± 0.059 
4. Discussion 
The drug treatment regimen for AD has not changed dramatically in over 20 years, 
with the current second-generation ChEIs, donepezil hydrochloride (FDA approved in 
1997), rivastigmine tartrate (FDA approved in 2000), and galantamine hydrobromide 
(FDA approved in 2001), providing the mainstay treatment for mild-to-moderate AD. In 
addition, memantine (FDA approved in 2003), an antagonist of the N-methyl-D-aspartate 
(NMDA) receptor involved in excitatory glutamatergic neurotransmission, can also be 
used as a monotherapy, combination therapy, or adjunct to ChEI treatment. A drawback 
to the use of ChEIs is potential for ADRs as well as concerns regarding their cost-effective-
ness [36,37]. Notably, tacrine, the first FDA approved ChEI (1993), was eventually re-
moved as a prescription medication due to concerns with off-target toxicity effects, par-
ticularly hepatotoxicity [38]. To address this unmet need to improve dose efficiency, and 
thereby reduce the likelihood of induction of undesired side-effects, and also to provide a 
more cost-effective medicine, we examined the potential benefits associated with novel 
dual-drug ChEI combinations. 
When assessed as single drugs, the ChEIs, donepezil, tacrine, berberine, and galan-
tamine, all proved useful and potent inhibitors of human or Torpedo californica AChE. 
Donepezil was the most effective ChEI and then tacrine, with these two inhibitors pro-
ducing IC50 values in the nanomolar range, similar to those published for rat brain homog-
enates [39]. Substrate (AChE) binding by a ChEI may be to a similar site [39], but AChE 
can potentially accommodate two ChEI molecules simultaneously. The catalytic region of 
AChE (the esteratic site) is located at the bottom of a narrow gorge and contains three 
essential amino acids that provide the catalytic triad [24,40]. Anti-cholinergic drugs can 
inhibit AChE via direct binding to the catalytic site or via binding to a peripheral anionic 
site (PAS) primarily composed of aromatic amino acids. A number of ChEIs, including 
donepezil, tacrine, berberine, and galantamine, can bind at the PAS, and binding at this 
site can contribute to reduced AChE activity [24,41–44]. 
Screening of human or Torpedo californica AChE inhibition with dual-drug combina-
tions revealed that BerTac, BerGal, and TacDon produced synergistic outcomes. For hu-
man AChE present within differentiated neurons, dual-drug synergism was also evi-
denced for these combinations as well as from DonGal, DonBer, and TacGal. The most 
potent synergism was attained via the BerGal combination and then the BerTac pairing. 
The potential benefit of synergistic inhibition by BerGal was a 72% reduction in total drug 
dose and a 66% reduction with BerTac. Reduced drug load would be expected to have a 
concomitant reduction of potential ADRs as well as improved cost-effectiveness. This is 
particularly pertinent for tacrine, given that excessive ADRs were responsible for its re-
moval from the drug market [36,38]. 
To assess potential neurotoxicity, cell viability of differentiated neurons was quanti-
fied as single drug and dual-drug combinations. For the single drug exposures, the order 
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of potency as a ChEI, donepezil > tacrine > berberine > galantamine, was mirrored with 
corresponding drug toxicity to cells (Tables 1 and 3). However, even for the most toxic 
drug, donepezil, (IC50 of 5.55 µM), the corresponding IC50 for AChE inhibition was only 
0.081 µM (Table 2). Hence, therapeutic ChEI activity would still be efficacious without 
induction of significant neuronal toxicity. 
Apart from BerGal, which was particularly well tolerated, each of the dual-drug com-
binations were of similar toxicity, and collectively, more toxic than donepezil (Table 3). 
Nevertheless, similar to application of individual drugs, the potency of dual-drug combi-
nations towards AChE (IC50s) were approximately two to three orders of magnitude lower 
than that for cell viability IC50s; indicative of useful drug application within a therapeutic 
index. 
The use of ChEIs for the treatment and management of AD may be improved through 
the use of dual-drug combinations or multi-drug targeting approaches [45–48]. The FDA 
approved concomitant use of memantine and ChEIs has primarily proved clinical effica-
cious and comparable to monotherapies, and for some studies provided additional benefit 
of reduced neurobehavioral symptoms [48]. 
In summary, there is an ongoing requirement for utilization of ChEIs with similar or 
improved clinical efficacy but with reduced ADRs. In the absence of newly available pre-
scription drugs, deployment of current ChEIs (donepezil or galantamine), redeployment 
of a past ChEI (tacrine), or employment of a new ChEI (berberine) as dual-drug combina-
tions, represent a potential means to achieve drug efficacy at lower drug doses able to 
diminish toxicity and increase drug cost-effectiveness. However, although dual-drug 
combinations are able to induce synergistic inhibition of AChE, individual drug pharma-
cokinetic profiles may yet hamper therapeutic utilization. For example, only donepezil 
and galantamine have relatively high oral bioavailability (compared to tacrine or berber-
ine), and only the former drug has a half-life of over 24 h, facilitating a single daily dosing 
regimen [11,49–51]. Hence, in vivo studies are required to validate these in vitro results 
and the potential for implementation of coordinated dual-drug ChEI treatments for AD. 
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